Alternate day fasting improves physiological and molecular markers of aging in healthy, non-obese humans
If you want to discuss the possibility of taking GLP-1s for Crohns, speak to your healthcare provider, who can determine whether youre a candidate for treatment, and help you weigh the pros and cons
What are the risks and warning signs to watch for
At 12 months, the on-medication MDS-UPDRS Part III score was 14.9 in the lixisenatide group versus 18.8 in the placebo group, a between-group difference of 3.08 points (P = 0.007) [3]
Sobo can better evaluate whether the plan is working, whether the dose should change, whether labs should be reviewed, or whether another approach may be more appropriate
Telomeres protect chromosomes from deterioration